CEO, Novo Nordisk
Sørensen isn't afraid to take calculated risks: Five years ago he jettisoned the drug maker's diabetes-pill research (while others were pouring money into it), betting instead that injected insulin would continue to be the most effective diabetes treatment. The bet paid off. The pill market shrank because of safety worries and patent expirations, and today Novo Nordisk is the world's biggest insulin producer. Sørensen has positioned the Danish company to keep profiting from the global epidemic: degludec, a new diabetes drug, is close to winning approvals. --OA
He's a pro-customer, tightfisted risk-taker who is conditioning Wall Street to embrace his erratic earnings. If you're running a business with high margins - watch out.